Physician profile
Omar Quiles
NPI 1154467553
$3,410.84
in general payments reported to CMS, 2019-2025
28 companies · $954 in 2025
The $954 reported for 2025 was more than what 87% of Physical Medicine & Rehabilitation providers received nationally (typical 2025 total: $138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $381 · 2020: $190 · 2022: $962 · 2023: $471 · 2024: $452 · 2025: $954.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,877.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,877.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $1,060.76 | 2022-2025 | Intellis Adaptivestim, Inceptiv, Synchromedii |
| Medtronic USA, INC. | $555.56 | 2019-2020 | |
| Nevro Corp. | $385.85 | 2022-2024 | Senza |
| Abbott Laboratories | $156.03 | 2022-2025 | Octrode |
| Vertos Medical, INC. | $142.90 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $128.97 | 2022-2023 | Seglentis |
| Globus Medical, INC. | $122.61 | 2025 | Senza |
| Boston Scientific Corporation | $120.59 | 2022-2025 | General - Pain Management, Wavewriter Alpha Prime 16 |
| Foundation Fusion Solutions, LLC | $82.56 | 2025 | |
| Biotronik Nro, INC. | $82.53 | 2025 | Prospera |
| Tersera Therapeutics LLC | $64.93 | 2025 | Prialt |
| Averitas Pharma INC. | $64.69 | 2023-2025 | Qutenza |
| Amgen INC. | $54.12 | 2022 | |
| Ibsa Pharma INC. | $47.96 | 2023-2024 | Tirosint, Licart, Tirosint |
| Radius Health, INC. | $46.48 | 2022 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Saluda Medical Americas, INC. | $40.65 | 2024-2025 | Evoke |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $37.79 | 2022-2025 | Relistor |
| Protega Pharmaceutials INC | $33.86 | 2025 | Roxybond |
| Abbvie INC. | $26.30 | 2023 | |
| Spr Therapeutics, INC | $20.78 | 2025 | Sprint Pns System |
| Lilly USA, LLC | $20.31 | 2022 | |
| Collegium Pharmaceutical, INC. | $19.72 | 2025 | Belbuca |
| Innovation Technologies INC | $17.38 | 2025 | Irrisept |
| Valinor Pharma, LLC | $16.34 | 2025 | Movantik |
| Fidia Pharma USA INC. | $16.30 | 2024 | Hymovis |
| Scilex Pharmaceuticals INC. | $15.76 | 2019 | |
| Curonix LLC | $14.94 | 2025 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Si-Bone, INC. | $14.17 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Omar Quiles listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.